Revolution Medicines posts investor presentation on RASONQUE FDA approval

Reuters2026/08/26 17:45

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

Revolution Medicines released an investor presentation covering U.S. FDA approval of RASONQUE (daraxonrasib) for metastatic pancreatic adenocarcinoma.
Label: adults with metastatic PDAC with at least one prior systemic therapy, or not candidates for multiagent systemic therapy.
Phase 3 RASolute 302: median overall survival 13.2 months vs 6.7 months; hazard ratio 0.40.
Median progression-free survival 7.2 months vs 3.6 months; hazard ratio 0.49.
Recommended dose 300 mg once daily; serious adverse reactions in 30% of patients.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Revolution Medicines Inc. published the original content used to generate this news brief on August 26, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

Revolution Medicines posts investor presentation on RASONQUE FDA approval

You may also like

Crypto prices